Mynzepli (Aflibercept)

Aflibercept is a fusion protein that binds VEGF‑A, VEGF‑B and placental growth factor with high affinity. By sequestering these ligands, it blocks activation of VEGF receptors on retinal endothelial cells, suppressing abnormal blood‑vessel growth and vascular leakage that cause macular edema.

The dosing regimen for Mynzepli is determined by the prescribing ophthalmologist based on the specific indication and patient response. Typically, the drug is delivered as a single‑use intravitreal injection, and the frequency of repeat injections is individualized.

Aflibercept’s pregnancy category is listed as unknown. It should only be used during pregnancy or lactation if the potential benefit justifies the potential risk to the fetus or infant. Clinicians should discuss risks with the patient and consider alternative therapies when appropriate.

To order Mynzepli, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain logistics) and import documentation.

Mynzepli (aflibercept) has a broader binding profile, targeting VEGF‑A, VEGF‑B and placental growth factor, whereas agents such as ranibizumab bind only VEGF‑A. Clinical studies suggest comparable efficacy in visual outcomes, with some data indicating longer dosing intervals for aflibercept in certain patients.

Mynzepli should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze the product or shake the vial. Keep it in the original packaging until use to maintain sterility and potency.

Mynzepli is given as a single‑use intravitreal injection performed by a qualified ophthalmologist under aseptic conditions. The medication is injected into the vitreous cavity of the eye using a sterile needle, typically in an outpatient setting.

Serious risks include endophthalmitis (a sight‑threatening eye infection), retinal detachment, and systemic arterial thromboembolic events such as stroke or myocardial infarction. Patients should be monitored closely for signs of infection, visual changes, or systemic vascular symptoms after injection.

Mynzepli is contraindicated in patients with known hypersensitivity to aflibercept or any component of the formulation, and it should be avoided in eyes with active ocular infection or recent intra‑ocular surgery until healed. Caution is also advised for patients with uncontrolled systemic vascular disease.